Friday, September 18, 2015 11:35:27 AM
Amazing that anyone listens to either of them anymore.
The article was an obvious attempt to officially shift the company's "laser like focus" from Flucide to herpecide.
But the question is: If herpecide is such an obvious and brilliant opportunity, why didn't the numerous consultants and crack management team make herpecide the initial priority? Ask yourself, what has changed? The simpler testing time and process has not changed. The less stringent manufacturing requirements for a topical vs. injectable have not changed. The market size for a herpes treatment has not changed. So why now?
Answer: Because scale up of Flucide is a bust. They have not even verified that they can do their self proclaimed next step of 500g. After years of struggling to cobble together 200g to get BASi started and they are stuck. Sure, more lab techs and phds but thas all to the benefit of Diwan's pocket.
As predicted, the company has now officially transitioned to the new flavor of the month. Not that herpecide wasn't in their pipeline, but it is now 100% what we will hear about moving forward. Just add HIV, Rabies, MERS, Ebola, Dengue…. BTW, notice how PHE and MERS is just completely silent? The company said PHE already had the materials, so it isn't a manufacturing issue. They also claimed it was an issue of PHE resources and Ebola was the priority. But what is the excuse now? Anyone else see a pattern of claiming interest by a foreign entity only to have it NEVER materialize and never be discussed again?
As soon as they feel too much pressure (or dropping SP) because of lack of progress, they trot out a new bright shiny object to distract from the reality of what is happening.
Them re-engaging with Cox is desperate and transparent.
I know, I know, time will tell. Funny, people say that, and time keeps saying the same thing.
2 more years before anything is through Tox (according to the company) As I have been saying, it won't happen.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM